NCCN肺癌指南（2009版） .doc
http://www.100md.com
参见附件(1457KB)。
NCCN Clinical Practice Guidelines in Oncology(tm)
Non-Small Cell
Lung Cancer
V.2.2009
Continue
www.nccn.org
NCCN(r)
Practice Guidelines
in Oncology - v.2.2009
Non-Small Cell Lung Cancer
Guidelines Index
NSCL Table of Contents
Staging, Discussion, References
* David S. Ettinger, MD/Chair ?
NCCN Non-Small Cell Lung Cancer Panel Members
Frederic W. Grannis, Jr., MD ?Raymond U. Osarogiagbon, MD
The Sidney Kimmel Comprehensive Cancer
Center at Johns Hopkins
Wallace Akerley, MD?
Huntsman Cancer Institute at the University of
Utah
* Gerold Bepler, MD, PhD?
H. Lee Moffitt Cancer Center & Research
Institute
Matthew G. Blum, MD?
Robert H. Lurie Comprehensive Cancer Center
of Northwestern University
Andrew Chang, MD?
University of Michigan Comprehensive Cancer
Center
City of Hope
Thierry Jahan, MD ?
UCSF Helen Diller Family Comprehensive
Cancer Center
Mohammad Jahanzeb, MD?
St. Jude Children's Research Hospital/University
of Tennessee Cancer Institute
David H. Johnson, MD?
Vanderbilt-Ingram Cancer Center
Anne Kessinger, MD?
UNMC Eppley Cancer Center at The Nebraska
Medical Center
*Ritsuko Komaki, MD§
The University of Texas M. D. Anderson Cancer
St. Jude Children's Research Hospital/University of
Tennessee Cancer Institute
Gregory A. Otterson, MD ?
Arthur G. James Cancer Hospital & Richard J.
Solove Research Institute at The Ohio State
University
Jyoti D. Patel, MD ?
Robert H. Lurie Comprehensive Cancer Center of
Northwestern University
Katherine M Pisters, MD ? ?
The University of Texas M. D. Anderson Cancer
Center
Karen Reckamp, MD, MS ?
City of Hope
Richard T. Cheney, MD1
Center
Francisco Robert, MD
?
Roswell Park Cancer Institute
*Mark G. Kris, MD ?
University of Alabama at Birmingham
Comprehensive Cancer Center
Lucian R. Chirieac, MD
1
Memorial Sloan-Kettering Cancer Center
Dana-Farber/Brigham and Women's Cancer
David J. Sugarbaker, MD
?
Center
* Thomas A. D'Amico, MD ?
Duke Comprehensive Cancer Center
Todd L. Demmy, MD ?
Roswell Park Cancer Institute
Steven J. Feigenberg, MD §
Fox Chase Cancer Center
Ramaswamy Govindan, MD ?
Siteman Cancer Center at Barnes-Jewish
Hospital and Washington University School of
Medicine
NCCN Guidelines Panel Disclosures
Quynh-Thu Le, MD §
Stanford Comprehensive Cancer Center
Inga T. Lennes, MD ?
Massachusetts General Hospital Cancer Center
Renato Martins, MD ?
Fred Hutchinson Cancer Research
Center/Seattle Cancer Care Alliance
Continue
Dana-Farber/Brigham and Women's Cancer Center
Douglas E. Wood, MD?
Fred Hutchinson Cancer Research Center/Seattle
Cancer Care Alliance
Stephen C. Yang, MD ?
The Sidney Kimmel Comprehensive Cancer Center
at Johns Hopkins
? Medical Oncology
? Surgery/Surgical oncology
§ Radiation oncology/Radiotherapy
1Pathology
? Hematology/Hematology oncology
* Writing Committee Member
Version 2.2009, 10/15/08 (c) 2008 National Comprehensive Cancer Network, Inc. All rights reserved.
These guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN.
NCCN(r)
Practice Guidelines
in Oncology - v.2.2009
Non-Small Cell Lung Cancer
Guidelines Index
NSCL Table of Contents
Staging, Discussion, References
Table of Contents
NCCN Non-Small Cell Lung Cancer Panel Members
Summary of Guidelines Updates
Lung Cancer Prevention and Screening (PREV-1)
Initial Evaluation and Clinical Stages (NSCL-1)
Evaluation and Treatment:
Stage 0 (Tis) (NSCL-16)
Stage I (T1-2, N0) and Stage II (T1-2, N1) (NSCL-2
)
For help using these documents,please click here
Staging
Discussion
References
Stage IIB (T3, N0) and Stage IIIA, IIIB (T3-4, N1) (NSCL-4
Stage IIIA (T1-3, N2) and Stage IIIB (T4, N0-1) (NSCL-6
Stage IIIB (T1-3, N3) (NSCL-9)
)
)
Stage IIIB (T4, N2-3) and Stage IIIB (T4: pleural or pericardial effusion) (NSCL-10
)
Clinical Trials:
The
NCCN
Stage IV (M1: solitary site and disseminated) (NSCL-11)
believes that the best management
Surveillance (NSCL-12
)
for any cancer patient is in a clinical
trial.Participation in clinical trials is
Therapy for Recurrence and Metastasis (NSCL-12
)
especially encouraged.
Occult (TX, N0, M0), Evaluation and Treatment (NSCL-16
Second Lung Primary, Evaluation and Treatment (NSCL-16
Principles of Pathologic Review (NSCL-A)
Principles of Surgical Resection (NSCL-B)
Principles of Radiation Therapy (NSCL-C)
Chemotherapy Regimens for Adjuvant Therapy (NSCL-D
Systemic Therapy for Advanced or Metastatic Disease (NSCL-E
Cancer Survivorship Care (NSCL-F)
Guidelines Index
Print the Non-Small Cell Lung Cancer Guideline
)
)
)
)
NCCNCategories of Evidence and
Consensus:All recommendations
are Category 2A unless otherwise
specified. SeeNCCNCategories of
Evidence and Consensus
Click here to find a clinical
trial at an NCCN Center
These guidelines are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment.
Any clinician seeking to apply or consult these guidelines is expected to use independent medical judgment in the context of individual clinical
circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network makes no representations nor warranties
of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. These......（后略) ......
NCCN Clinical Practice Guidelines in Oncology(tm)
Non-Small Cell
Lung Cancer
V.2.2009
Continue
www.nccn.org
NCCN(r)
Practice Guidelines
in Oncology - v.2.2009
Non-Small Cell Lung Cancer
Guidelines Index
NSCL Table of Contents
Staging, Discussion, References
* David S. Ettinger, MD/Chair ?
NCCN Non-Small Cell Lung Cancer Panel Members
Frederic W. Grannis, Jr., MD ?Raymond U. Osarogiagbon, MD
The Sidney Kimmel Comprehensive Cancer
Center at Johns Hopkins
Wallace Akerley, MD?
Huntsman Cancer Institute at the University of
Utah
* Gerold Bepler, MD, PhD?
H. Lee Moffitt Cancer Center & Research
Institute
Matthew G. Blum, MD?
Robert H. Lurie Comprehensive Cancer Center
of Northwestern University
Andrew Chang, MD?
University of Michigan Comprehensive Cancer
Center
City of Hope
Thierry Jahan, MD ?
UCSF Helen Diller Family Comprehensive
Cancer Center
Mohammad Jahanzeb, MD?
St. Jude Children's Research Hospital/University
of Tennessee Cancer Institute
David H. Johnson, MD?
Vanderbilt-Ingram Cancer Center
Anne Kessinger, MD?
UNMC Eppley Cancer Center at The Nebraska
Medical Center
*Ritsuko Komaki, MD§
The University of Texas M. D. Anderson Cancer
St. Jude Children's Research Hospital/University of
Tennessee Cancer Institute
Gregory A. Otterson, MD ?
Arthur G. James Cancer Hospital & Richard J.
Solove Research Institute at The Ohio State
University
Jyoti D. Patel, MD ?
Robert H. Lurie Comprehensive Cancer Center of
Northwestern University
Katherine M Pisters, MD ? ?
The University of Texas M. D. Anderson Cancer
Center
Karen Reckamp, MD, MS ?
City of Hope
Richard T. Cheney, MD1
Center
Francisco Robert, MD
?
Roswell Park Cancer Institute
*Mark G. Kris, MD ?
University of Alabama at Birmingham
Comprehensive Cancer Center
Lucian R. Chirieac, MD
1
Memorial Sloan-Kettering Cancer Center
Dana-Farber/Brigham and Women's Cancer
David J. Sugarbaker, MD
?
Center
* Thomas A. D'Amico, MD ?
Duke Comprehensive Cancer Center
Todd L. Demmy, MD ?
Roswell Park Cancer Institute
Steven J. Feigenberg, MD §
Fox Chase Cancer Center
Ramaswamy Govindan, MD ?
Siteman Cancer Center at Barnes-Jewish
Hospital and Washington University School of
Medicine
NCCN Guidelines Panel Disclosures
Quynh-Thu Le, MD §
Stanford Comprehensive Cancer Center
Inga T. Lennes, MD ?
Massachusetts General Hospital Cancer Center
Renato Martins, MD ?
Fred Hutchinson Cancer Research
Center/Seattle Cancer Care Alliance
Continue
Dana-Farber/Brigham and Women's Cancer Center
Douglas E. Wood, MD?
Fred Hutchinson Cancer Research Center/Seattle
Cancer Care Alliance
Stephen C. Yang, MD ?
The Sidney Kimmel Comprehensive Cancer Center
at Johns Hopkins
? Medical Oncology
? Surgery/Surgical oncology
§ Radiation oncology/Radiotherapy
1Pathology
? Hematology/Hematology oncology
* Writing Committee Member
Version 2.2009, 10/15/08 (c) 2008 National Comprehensive Cancer Network, Inc. All rights reserved.
These guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN.
NCCN(r)
Practice Guidelines
in Oncology - v.2.2009
Non-Small Cell Lung Cancer
Guidelines Index
NSCL Table of Contents
Staging, Discussion, References
Table of Contents
NCCN Non-Small Cell Lung Cancer Panel Members
Summary of Guidelines Updates
Lung Cancer Prevention and Screening (PREV-1)
Initial Evaluation and Clinical Stages (NSCL-1)
Evaluation and Treatment:
Stage 0 (Tis) (NSCL-16)
Stage I (T1-2, N0) and Stage II (T1-2, N1) (NSCL-2
)
For help using these documents,please click here
Staging
Discussion
References
Stage IIB (T3, N0) and Stage IIIA, IIIB (T3-4, N1) (NSCL-4
Stage IIIA (T1-3, N2) and Stage IIIB (T4, N0-1) (NSCL-6
Stage IIIB (T1-3, N3) (NSCL-9)
)
)
Stage IIIB (T4, N2-3) and Stage IIIB (T4: pleural or pericardial effusion) (NSCL-10
)
Clinical Trials:
The
NCCN
Stage IV (M1: solitary site and disseminated) (NSCL-11)
believes that the best management
Surveillance (NSCL-12
)
for any cancer patient is in a clinical
trial.Participation in clinical trials is
Therapy for Recurrence and Metastasis (NSCL-12
)
especially encouraged.
Occult (TX, N0, M0), Evaluation and Treatment (NSCL-16
Second Lung Primary, Evaluation and Treatment (NSCL-16
Principles of Pathologic Review (NSCL-A)
Principles of Surgical Resection (NSCL-B)
Principles of Radiation Therapy (NSCL-C)
Chemotherapy Regimens for Adjuvant Therapy (NSCL-D
Systemic Therapy for Advanced or Metastatic Disease (NSCL-E
Cancer Survivorship Care (NSCL-F)
Guidelines Index
Print the Non-Small Cell Lung Cancer Guideline
)
)
)
)
NCCNCategories of Evidence and
Consensus:All recommendations
are Category 2A unless otherwise
specified. SeeNCCNCategories of
Evidence and Consensus
Click here to find a clinical
trial at an NCCN Center
These guidelines are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment.
Any clinician seeking to apply or consult these guidelines is expected to use independent medical judgment in the context of individual clinical
circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network makes no representations nor warranties
of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. These......（后略) ......
相关资料1：